3 Dividend Stocks to Buy Hand Over Fist in March
Get paid to own a stock whether it moves higher or lower. What a concept! And it's one that any investor who buys dividend stocks can enjoy. Three Motley Fool contributors believe they've identified dividend stocks to buy hand over fist in March. Here's why they picked Gilead Sciences (NASDAQ: GILD), Novartis (NYSE: NVS), and Pfizer (NYSE: PFE).
David Jagielski (Gilead Sciences): HIV drugmaker Gilead Sciences has been struggling this year after disappointing results involving Trodelvy in a recent lung cancer trial sent the stock reeling. But the company is by no means in bad shape; Trodelvy is still a promising cancer drug; and the sell-off could prove to be temporary.
A key reason this is still an excellent buy is the growing diversification that Gilead's portfolio possesses. In addition to having a strong HIV business that generated more than $18 billion in revenue last year (growing at a rate of 6%), Gilead has also been expanding into other areas, such as oncology. Last month, it announced plans to acquire CymaBay Therapeutics in a move that would strengthen its portfolio of potential liver disease products.
Source Fool.com
